科伦[Ta药ble业_S（tock 0N 0am 2e 4R 2p 2tT .y Spe Z] ） 公司研究/公司点评 23FY 三发驱动创新增长，结构优化降本增效 [T投 ab资 le_评 R级 an： k]买 入（维持） 主要观点： 报告日期： 2024-04-29 ⚫ 事件1 2024年4月25日，科伦药业发布2023年年度业绩报告，报告期内公 [收Ta盘bl价e_（Ba元se）D ata] 32.83 司实现营业收入214.54亿元，同比+12.69%；归母净利润24.56亿元， 近12个月最高/最低（元） 33.28/21.60 同比+44.03%；扣非归母净利润23.66亿元，同比+43.77%。单季度来 总股本（百万股） 1602 流通A股（百万股） 1307 看，公司2023Q4收入为57.11亿元，同比+12.02%；归母净利润为4.93 流通股比例（%） 81.58% 亿元，同比+64.31%；扣非归母净利润为4.45亿元，同比+61.89%。 ⚫ 事件2 总市值（亿元） 525.8 流通市值（亿元） 429.1 同日，科伦药业发布 2024 年一季度业绩报告，报告期内公司实现营业 收入6 ...

[Table_StockInfo] 买入 2024年 04月 26日 （上调） 证券研究报告•2023年报&2024年一季报点评 当前价：3 2.40元 科伦药业（002422） 医 药生物 目标价：3 9.38元（6个月） 输液业务表现亮眼，创新转型加速兑现 投资要点 西南证券研究发展中心 [T ab事le件_S：um公m司a发ry布] 2023 年年报及 2024 年一季报，2023 年公司实现营业收入 214.5 亿元，同比增长 12.7%；归母净利润 24.6 亿元，同比增长 44%；扣非 [分Ta析bl师e_：Au杜th向or阳] 归母净利润 23.7亿元，同比增长 43.8%。2024Q1 实现营业收入 62.2亿元， 执业证号：S1250520030002 同比增长 10.3%；归母净利润 10.3 亿元，同比增长 26%；扣非归母净利润 电话：021-68416017 9.9亿元，同比增长25.7%，业绩符合预期。 邮箱：duxy@swsc.com.cn  科伦博泰创新平台持续推进，商业化值得期待。2023 年科伦博泰实现营收 15.4 亿元（+91.6%），来自默沙东的许可及合作协议收入 ...

[Table_StockInfo] 买入 2024年 04月 26日 （上调） 证券研究报告•2023年报&2024年一季报点评 当前价：3 2.40元 科伦药业（002422） 医 药生物 目标价：3 9.38元（6个月） 输液业务表现亮眼，创新转型加速兑现 投资要点 西南证券研究发展中心 [T ab事le件_S：um公m司a发ry布] 2023 年年报及 2024 年一季报，2023 年公司实现营业收入 214.5 亿元，同比增长 12.7%；归母净利润 24.6 亿元，同比增长 44%；扣非 [分Ta析bl师e_：Au杜th向or阳] 归母净利润 23.7亿元，同比增长 43.8%。2024Q1 实现营业收入 62.2亿元， 执业证号：S1250520030002 同比增长 10.3%；归母净利润 10.3 亿元，同比增长 26%；扣非归母净利润 电话：021-68416017 9.9亿元，同比增长25.7%，业绩符合预期。 邮箱：duxy@swsc.com.cn  科伦博泰创新平台持续推进，商业化值得期待。2023 年科伦博泰实现营收 15.4 亿元（+91.6%），来自默沙东的许可及合作协议收入 ...

[Table_Page] 年报点评|化学制药 证券研究报告 [科Table_伦Title] 药业（002422.SZ） [公Tab司le_I评nves级t] 买入 当前价格 31.30元 三发驱动业绩增长，创新研发高效推进 合理价值 48.49元 前次评级 买入 [ 核Tabl 心e_Su 观mm 点ary] ： 报告日期 2024-04-26 ⚫ 事件：公司发布2023年报及2024年一季度：2023年营收214.54亿 相[Ta对ble市_Pi场cQu表ote现] 元，同比+12.69%；归母净利润24.56亿元，同比+44.03%；扣非归母 净利润23.66亿元，同比+43.77%。2024年Q1实现营收62.19亿元， 10% 同比+10.32%；归母净利润10.26亿元，同比+26%；扣非归母净利润 3% 9.92 亿元，同比+25.67%。业绩增长主要驱动原因包括：（1）输液、 -4%04/23 06/23 08/23 10/23 12/23 02/24 04/24 非输液制剂板块产品结构优化；（2）原料药中间体主要产品销量和价 -11% 格同比上涨；（3）科伦博泰确定默沙东相关里程碑款；（4）有 ...

口口 科伦药业20240425_智能速览 2024年04月26日00:57 关键词 科伦药业 科伦博泰 川宁生物 原料药 中间体 销售 青霉素 阿莫西林 氨苄西林 头孢类 TADC 仿制药 创新 药 集采 市场份额 科伦 增长 净利润 销售费用 股东回报 全文摘要 化以及监管环境的严格，并展现了行业参与者对创新和高质量发展的持续追求。 章节速览 ● 00:00 2023年抗生素原料药及中间体市场展望 由于新冠疫情的影响和全球市场需求的增长，抗生素原料药及中间体市场呈现出旺盛的需求。特别是在 硫氰酸红霉素和青霉素板块，因供应链紧张和产量减少，市场价格持续上涨。特别是2022年以来，相关 企业如川宁生物的中间体销售额表现良好，预计未来市场将继续保持高位。此外，尽管面临来自国外的 竞争威胁，但中国作为全球抗生素产业链的核心优势不容忽视，预示着中国企业在该领域的长期竞争 力。 ● 06:39 国泰医疗产品研发与市场策略 国泰医疗在过去一年在临床研究、肿瘤药物开发、仿制药和创新药领域取得显著进展，特别是在创新型 生物药和治疗方法的研发上取得了重大突破。公司主要围绕四个方向进行了介绍：临床管线进展情况、 肿瘤相关药物研发 ...

公[Ta司ble点_H评ead报er] 告●化学制药 2024 年 04 月25 日 [Table_Title] 输液龙头业绩亮眼，需求旺盛可持续性 [ 科Ta 伦ble 药_S 业toc (k 0C 0o 2d 4e] 2 2) 较高 [Tabl推e_In荐ves tRank] (维持) 核心观点： 分析师 程培 ⚫⚫ [事 Ta件 ble： _S公 um司 m发 ar布 y] 2023年年报和 2024年一季报，2023年公司实现收入 214.54 [Table_Authors] 亿元，同比增长 12.69%，实现归母净利润 24.56亿元，同比增长 44.03%。2024 ：021-20257805 年一季度公司实现收入 62.19亿元，同比增长 10.32%，实现归母净利润 10.26 ：chengpei_yj@chinastock.com.cn 亿元，同比增长 26%。 分析师登记编码：S0130522100001 ⚫ 输液持续超预期，需求旺盛&结构优化，未来仍将快速增长。2023年公司 输液板块收入 101.09 亿元，同比增长 6.96%；销量 43.78 亿瓶/袋，同比增长 孙怡 10.6 ...

科伦药业（002422.SZ） 业绩符合预期，三发驱动加快创新转型 科伦药业发布 2023 年年报。2023 年公司实现营业收入 214.54 亿元，同比增长 12.69%，归母净利润 24.56 亿元，同比增长 44.03%；归母扣非净利润 23.66 亿 元，同比增长 43.77%。 Q4 单季度营业收入 57.11 亿元，同比增长 12.02%，归母净利润 4.93 亿元，同比 增长 64.31%，归母扣非净利润 4.45 亿元，同比增长 65.32%。 科伦药业发布 2024 年一季报。2024 年一季度公司实现营业收入 62.19 亿元，同 比增长 10.32%，归母净利润 10.26 亿元，同比增长 26.00%；归母扣非净利润 9.92 亿元，同比增长 25.67%。 业绩符合预期，主业高增长、国际化创新持续推进，三发驱动加快转型。 收入端，公司 2023Q4-2024Q1 收入同比增长分别为 12.02%、10.32%、保持稳 定增长态势。2023 年主要增长点包括： ➢ 输液产品销售数量增加，持续优化产品结构，密闭式输液量占比提升 4.25pp； 实现营业收入 101.09 亿元，同比增长 ...

四川科伦药业股份有限公司2024年第一季度报告 证券代码：002422 证券简称：科伦药业 公告编号：2024-064 四川科伦药业股份有限公司 2024 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 □是 否 ...

Dividend Distribution - The company plans to distribute a cash dividend of 8 yuan per 10 shares, totaling 1,590,876,008 shares[2] Risk Factors - The company faces risks including industry policy changes, market risks, environmental risks, R&D innovation risks, and quality control risks[2] Subsidiaries and Branches - The company has multiple subsidiaries and branches, including Sichuan Kelun Pharmaceutical Co., Ltd., Hunan Kelun Pharmaceutical Co., Ltd., and Jiangxi Kelun Pharmaceutical Co., Ltd.[5] - The company's subsidiaries are involved in various sectors such as pharmaceutical manufacturing, drug research, and medical trade[5] - The company has a significant presence in regions like Sichuan, Hunan, Jiangxi, and Yunnan through its subsidiaries[5] - The company's subsidiaries include specialized entities like the Sichuan Kelun Pharmaceutical Research Institute and the Suzhou Kelun Pharmaceutical Research Institute[5] - The company has a diverse portfolio of subsidiaries, including those focused on biotechnology, agricultural development, and medical technology[5] - The company's subsidiaries are engaged in both domestic and international markets, with entities like Kelun International Development Co., Ltd.[5] - The company's subsidiaries are involved in various stages of the pharmaceutical supply chain, from research and development to sales and distribution[5] - The company's subsidiaries include entities focused on packaging, such as Heilongjiang Kelun Pharmaceutical Packaging Co., Ltd.[5] - Kelun Pharmaceutical has subsidiaries such as Kelun International Medicine, Qingshan Likang Medicine, and Kelun Botai Biopharmaceutical[6] Company Information - Kelun Pharmaceutical's stock code is 002422, listed on the Shenzhen Stock Exchange[9] - The company's registered address is at the South Second Road, Xindu Satellite City Industrial Development Zone, Chengdu, with a postal code of 610500[9] - Kelun Pharmaceutical's office is located at No. 36 Baihua West Road, Qingyang District, Chengdu, with a postal code of 610071[9] - The company's website is http://www.kelun.com, and the email address is kelun@kelun.com[9] - The Board Secretary is Feng Hao, and the Securities Affairs Representative is Wang Mengran[10] - The company's legal representative is Liu Gexin[9] - Kelun Pharmaceutical's annual report is disclosed on the Shenzhen Stock Exchange website and major financial newspapers[12] - The company has not changed its main business or controlling shareholders since its listing[13] Financial Performance - Revenue for 2023 reached RMB 21.45 billion, a 12.69% increase compared to the adjusted 2022 revenue of RMB 19.04 billion[15] - Net profit attributable to shareholders in 2023 was RMB 2.46 billion, a 44.03% increase from the adjusted 2022 figure of RMB 1.71 billion[15] - Operating cash flow surged by 70.68% to RMB 5.34 billion in 2023, compared to RMB 3.13 billion in 2022[15] - Total assets grew by 6.57% to RMB 36.45 billion at the end of 2023, up from RMB 34.21 billion in 2022[16] - Shareholders' equity increased by 25.03% to RMB 19.67 billion in 2023, compared to RMB 15.73 billion in 2022[16] - Basic earnings per share rose by 38.52% to RMB 1.69 in 2023, up from RMB 1.22 in 2022[15] - Weighted average return on equity improved to 14.07% in 2023, up 2.37 percentage points from 11.70% in 2022[15] - Government subsidies received in 2023 amounted to RMB 159.82 million, a decrease from RMB 178.43 million in 2022[21] - The company's total revenue for 2023 was 21.46 billion yuan, with a year-on-year increase of 7.38%[92] - The revenue from the infusion products segment was 10.11 billion yuan, accounting for 47.12% of total revenue, with a year-on-year growth of 6.96%[91] - The revenue from non-infusion products was 9.06 billion yuan, accounting for 42.21% of total revenue, with a year-on-year growth of 7.85%[91] - The revenue from R&D projects increased significantly by 105.95% to 1.55 billion yuan[91] - International business revenue surged by 84.80% to 2.59 billion yuan, accounting for 12.06% of total revenue[91] - The gross profit margin for the pharmaceutical manufacturing industry was 53.45%, with a slight increase of 0.98% compared to the previous year[92] - The sales volume of infusion products increased by 10.60% to 4.38 billion bottles/bags, while production volume increased by 11.58% to 4.47 billion bottles/bags[94] - The company's direct sales revenue was 9.89 billion yuan, accounting for 46.11% of total revenue, with a year-on-year growth of 9.45%[91] - The cost of R&D projects increased by 197.37% to 748.82 million yuan, reflecting the company's increased investment in innovation[95] R&D and Innovation - Kelun Pharma has invested a cumulative total of 12.3 billion yuan in R&D innovation since 2013[26] - Kelun Pharma has 646 varieties of pharmaceutical products with 1022 specifications, including 135 varieties of infusion products with 297 specifications[33] - Kelun Pharma has 47 varieties (67 specifications) selected in the national centralized drug procurement, making it one of the top suppliers[26] - Kelun Pharma's self-developed Keli Bag® has 270 patents and has won the National Science and Technology Progress Award[24][25] - Kelun Pharma's production line has obtained GMP certification from Japan's PMDA, allowing sales in Japan[25] - Kelun Pharma has 6 enterprises selected as green factories in the Ministry of Industry and Information Technology's green manufacturing system construction demonstration[23] - Kelun Pharma has established a large-scale industrial production system in the antibiotic intermediate field, with products such as thiocyanate erythromycin and cephalosporin intermediates ranking among the top globally[25] - Kelun Pharma has 308 varieties of drugs listed in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2023 edition)[33] - Kelun Pharma has 135 varieties of drugs included in the National Essential Drug List (2018 edition)[33] - Kelun Pharma has 67 varieties of drugs listed in the OTC drug catalog[33] - The company signed an innovative R&D project cooperation agreement with MSD, resulting in increased revenue and profits[37] - The company increased its R&D expenses year-on-year, continuing to advance its "innovation-driven" strategy[38] - The company has established a comprehensive R&D system with multiple technology categories and full-function platforms, focusing on high-end generics and innovative research[43] - The company's R&D efficiency improved significantly, with 45 generic drugs approved for production and 4 approved for clinical trials in 2023[49] - The company's cumulative number of products selected in national centralized drug procurement reached 47 (67 specifications) by the 9th round[50] - Kelun Pharma's new drug approvals include Ethylsulfonic Acid Nintedanib Soft Capsule for systemic sclerosis-related interstitial lung disease and progressive fibrosing interstitial lung disease, becoming the second approved manufacturer[52] - Fumarate Vonoprazan Tablets for acid-related gastrointestinal diseases were approved for production, making Kelun the third manufacturer[52] - Kelun Pharma's Cefmetazole Sodium/Sodium Chloride Injection for bacterial infections was approved for production, also as the third manufacturer[52] - Gadobutrol Injection for diagnostic imaging was approved for production, with Kelun being the third manufacturer[52] - Enzalutamide Soft Capsule for tumors was approved for production, making Kelun the third manufacturer[52] - Kelun Pharma's Citicoline Sodium Injection passed the consistency evaluation as the first manufacturer, targeting consciousness disorders after craniocerebral trauma and brain surgery[52] - Lactated Ringer's Injection (Hunan Kelun) passed the consistency evaluation as the first manufacturer, used for fluid balance[52] - Amino Acid Glucose Injection passed the consistency evaluation as the first manufacturer, targeting parenteral nutrition[52] - Kelun Pharma's ω-3 Fish Oil Medium and Long Chain Fat Emulsion/Amino Acid (16)/Glucose (30%) Injection for parenteral nutrition is under production application as the first generic[54] - Rotigotine Transdermal Patch for Parkinson's disease is under production application as the first generic[54] - 6 clinical studies were approved by NMPA in 2023, including 1 first-time clinical approval and 5 new or combination therapy approvals[58] - SKB410 for advanced solid tumors received clinical approval in February 2023[58] - SKB264/MK-2870 combined with Osimertinib for EGFR-mutated non-small cell lung cancer received clinical approval in January 2023[58] - KL590586 capsule (A400) for medullary thyroid cancer received clinical approval in July 2023[58] - SKB264 for EGFR-TKI treatment-failed EGFR-mutated non-squamous non-small cell lung cancer received clinical approval in July 2023[58] - SKB264 combined with A167 for HR+/HER2- breast cancer received clinical approval in September 2023[58] - 30+ innovative drug projects are under development, focusing on oncology, autoimmune, inflammatory, and metabolic diseases[57] - Injection of Paclitaxel (Albumin-bound) has been approved for market launch[56] - Bupivacaine Liposome Injection has been submitted for production approval[56] - Multiple products, including Aripiprazole Long-Acting Injection and Brexpiprazole Oral Film, are undergoing clinical studies[56] - SKB264 received its fourth Breakthrough Therapy Designation (BTD) in March 2024 for first-line treatment of unresectable locally advanced, recurrent, or metastatic PD-L1 negative TNBC patients[60] - SKB264's Phase III registration study for TNBC completed enrollment in August 2023 and met its primary endpoint[63] - SKB264's New Drug Application (NDA) for TNBC was accepted by the NMPA in December 2023 and included in the priority review and approval process[63] - SKB264's Phase II expansion study data for TNBC was presented at the SABCS conference in December 2023[64] - SKB264's Phase III registration study for HR+/HER2- breast cancer (2L+) was initiated in November 2023[65] - A166's NDA for HER2+ breast cancer (3L+) was accepted by the NMPA in May 2023, and its Phase III study for HER2+ breast cancer was initiated in June 2023[69] - A140's market application was accepted by the NMPA in September 2023, making it the first domestic cetuximab biosimilar to apply for market approval[59] - A400's Phase II study for NSCLC was initiated in Q2 2023, and its Phase I data for RET-altered advanced solid tumors was presented at the ASCO annual meeting in June 2023[70] - SKB264's Phase II study for EGFR-mutant NSCLC (2L) and Phase II registration study (3L) were approved and initiated enrollment in the second half of 2023[66] - SKB264's Phase II basket study for NSCLC, including a cohort combining with osimertinib, was approved by the NMPA in January 2023[68] - The company's R&D pipeline includes A400 for RET fusion-positive solid tumors, A296 (STING agonist) in Phase I, and A223 (JAK1/2 inhibitor) for rheumatoid arthritis and alopecia areata in Phase II[71] - The company's R&D personnel increased to 2,612 in 2023, up 2.27% from 2,554 in 2022[114] - R&D investment reached 1,952,595,769 yuan in 2023, a 7.59% increase from 1,814,894,798 yuan in 2022[115] Sales and Marketing - The company's sales model has shifted from service-oriented to business expansion-oriented, supported by a nationwide sales layout[36] - The company's marketing strategy shifted from product sales to brand marketing, focusing on patient-centered and clinical value-oriented approaches[77] - The company's infusion business achieved sales revenue of 10.109 billion yuan, a year-on-year increase of 6.96%, with sales volume reaching 4.378 billion bottles/bags, up 10.60% year-on-year[78] - Levofloxacin Sodium Chloride Injection, a new consistency evaluation product, generated sales revenue of 488 million yuan, a year-on-year increase of 8.01%, ranking first in market share among selected companies in the national centralized procurement[78] - Moxifloxacin Hydrochloride Sodium Chloride Injection saw a sales volume increase of 175.11% year-on-year due to market recovery and expanded centralized procurement regions[78] - The parenteral nutrition segment sold over 20 million bags in 2023, with the three-chamber bag "Duozhen" achieving sales of 6.13 million bags[78] - Non-infusion drug sales revenue decreased by 6.93% to 3.955 billion yuan[80] - Sales revenue of male health product (Dapoxetine Hydrochloride Tablets) dropped by 84.07% to 34 million yuan[80] - Sales revenue of Kangfuxin Liquid declined by 36.17% to 227 million yuan[80] - Sales revenue of Escitalopram Oxalate (Bailuote) fell by 43.57% to 194 million yuan[80] - Sales volume of Albumin-bound Paclitaxel for Injection (Kerui Fei) increased by 93.19% despite a 32.74% drop in sales revenue[81] - Empagliflozin Tablets (Ketang En) sales revenue surged by 79.46% to 224 million yuan[81] - Plastic water needle sales reached 652 million units, up 20.78%[81] - Antibiotic intermediates and APIs revenue grew by 23.78% to 4.843 billion yuan[84] - Overseas revenue increased by 83.97% to 2.572 billion yuan[86] - Total operating revenue rose by 12.69% to 21.454 billion yuan[90] - The company's total revenue for 2023 was 21.46 billion yuan, with a year-on-year increase of 7.38%[92] - The revenue from the infusion products segment was 10.11 billion yuan, accounting for 47.12% of total revenue, with a year-on-year growth of 6.96%[91] - The revenue from non-infusion products was 9.06 billion yuan, accounting for 42.21% of total revenue, with a year-on-year growth of 7.85%[91] - The revenue from R&D projects increased significantly by 105.95% to 1.55 billion yuan[91] - International business revenue surged by 84.80% to 2.59 billion yuan, accounting for 12.06% of total revenue[91] - The gross profit margin for the pharmaceutical manufacturing industry was 53.45%, with a slight increase of 0.98% compared to the previous year[92] - The sales volume of infusion products increased by 10.60% to 4.38 billion bottles/bags, while production volume increased by 11.58% to 4.47 billion bottles/bags[94] - The company's direct sales revenue was 9.89 billion yuan, accounting for 46.11% of total revenue, with a year-on-year growth of 9.45%[91] - The cost of R&D projects increased by 197.37% to 748.82 million yuan, reflecting the company's increased investment in innovation[95] Corporate Governance - The company's board of directors consists of 7 members, including 3 independent directors, and has established five specialized committees to provide professional opinions for decision-making[162] - The company has a complete supply, R&D, production, and sales system, operating independently and making decisions autonomously without interference from controlling shareholders[167] - The company's assets are independent and complete, with no instances of being occupied by shareholders or related parties[168] - The company has an independent and complete labor, personnel, and salary management system, with senior management and financial personnel working exclusively for the company[169] - The company has established functional departments that are independent in personnel, office space, and management systems, free from interference by shareholders or other entities[170] - The company has an independent financial department with dedicated personnel, an independent financial accounting system, and operates independently without sharing bank accounts with controlling shareholders or related parties[171] - The participation rate of investors in the 2023 First Extraordinary General Meeting was 48.47%[172] - The participation rate of investors in the 2023 Second Extraordinary General Meeting was 46.68%[172] - The participation rate of investors in the 2022 Annual General Meeting was 46.68%[173] - The participation rate of investors in the 2023 Third Extraordinary General Meeting was 46.68%[173] - Chairman Liu Gexin holds 379,128,280 shares, with no changes during the reporting period[174] - Director and General Manager Liu Sichuan holds 8,346,286 shares, with no changes during the reporting period[174] - Vice President and Board Secretary Feng Hao increased his holdings by 37,000 shares, totaling 511,068 shares[175] - Vice President and CFO Lai Degui increased his holdings by 37,000 shares, totaling 525,698 shares[175] - The total number of shares held by directors, supervisors, and senior executives at the end of the period was 389,740,199[175] - Director Shao Wenbo resigned on March 1, 2024, due to personal reasons[176] - Liu Gexin, born in 1951, is the Chairman and Party Secretary of the company, with a postgraduate degree and senior engineer title. He has been the Chairman since 1996 and has received numerous awards and honors, including the National Labor Model in 2005 and the National Science and Technology Progress Award in 2015[177] - Liu Sichuan, born in 1984, is the Director and General Manager of the company, with a master's degree. He has been the General Manager since 2015 and has received several awards, including the National Advanced Individual in the Fight

【午间公告：科伦药业子公司核心产品获突破性疗法认定】财联社3月13日电，午间多家上市公司发布 公告，具体如下： ①科伦药业：公司控股子公司科伦博泰核心产品SKB264 (MK-2870)就一线治疗不可 手术切除的局部晚期、复发或转移性PD-L1阴性TNBC获国家药品监督管理局突破性疗法认定。 ②豪恩 汽电：公司以自有资金向子公司惠州汽电进行增资，增资金额为1.5亿元，增资后惠州汽电的注册资本 将由5000万元增至2亿元。本次增资完成后，公司仍持有惠州汽电100%股权。 ...